Olaparib (AZD2281)

For research use only.

Catalog No.S1060 Synonyms: Ku-0059436

493 publications

Olaparib (AZD2281) Chemical Structure

Molecular Weight(MW): 434.46

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1. Olaparib induces significant autophagy that is associated with mitophagy in cells with BRCA mutations.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 91 In stock
USD 57 In stock
USD 70 In stock
USD 150 In stock
USD 267 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Olaparib (AZD2281) has been cited by 493 publications

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1. Olaparib induces significant autophagy that is associated with mitophagy in cells with BRCA mutations.
Features A potent PARP inhibitor (currently in late stage clinical trials).
Targets
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
1 nM 5 nM
In vitro

Olaparib would act against BRCA1 or BRCA2 mutations. Olaparib is not sensitive to tankyrase-1 (IC50 >1 μM). Olaparib could ablate the PARP-1 activity at concentrations of 30-100 nM in SW620 cells. Olaparib is hypersensitive to BRCA1-deficient cell lines (MDA-MB-463 and HCC1937), compared with BRCA1- and BRCA2-proficient cell lines (Hs578T, MDA-MB-231, and T47D). [1] Olaparib is strongly sensitive to KB2P cells due to suppression of base excision repair by PARP inhibition, which may result in the conversion of single-strand breaks to double-strand breaks during DNA replication, thus activating BRCA2-dependent recombination pathways. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KP3.33 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETaUmo1KGR? MmjsTWM2OD13LkewOUAh|ryPIB?= MWmxPFU2QTZzMx?=
KP6.3 NVPTeHA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUK0JIQ> M{XyfGlEPTB;MUCuOFI5KM7:TTC= MkHKNVg2PTl4MUO=
KP7.7 M3zUS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLXOEBl Mn\oTWM2OD13NzDuUUA> NUPTeWRVOTh3NUm2NVM>
KB2P3.4 M1TVXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fUXVQh\A>? MYXJR|UxRTF{NDDNJC=> MYexPFU2QTZzMx?=
KB2P1.21 NGPKS5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1WyS|Qh\A>? NVnOclN{UUN3ME24PVA4KG6PIB?= NGfIclEyQDV3OU[xNy=>
U373-MG M4DDc2N6fG:2b4jpZ{BCe3OjeR?= NH7xTogyKM7:TTC= M3zWeFI1KGh? M{i4XGlv[3KnYYPld{Bz[WSrYYTpc44he2Wwc3n0bZZqfHl? MX2xPFk2PDdzMh?=
T98G M4i5Z2N6fG:2b4jpZ{BCe3OjeR?= M1HmO|Eh|ryPIB?= MkO5NlQhcA>? MlHETY5kemWjc3XzJJJi\GmjdHnvckB{\W6|aYTpeol1gQ>? M1\SRVE5QTV2N{Gy
U87-MG NXH6cINjS3m2b4TvfIlkKEG|c3H5 MVexJO69VSB? MY[yOEBp NHfwcHdKdmO{ZXHz[ZMhemGmaXH0bY9vKHOnboPpeIl3cXS7 NILXO4IyQDl3NEexNi=>
UVW MWTDfZRwfG:6aXOgRZN{[Xl? NEXOSnA2ODBibl2= NV23U5NwOjRiaB?= NW\KUGNQUW6lcnXhd4V{KHKjZHnheIlwdiC|ZX7zbZRqfmm2eR?= NXX6bGtEOTh7NUS3NVI>
HeLa NX3KTGFkTnWwY4Tpc44hSXO|YYm= M3HvflUxOCCwTR?= M2jCeVQhcA>? MUjDZZV{\XNiYTDtc4Rme3RiZHXsZZkhcW5icnXqc4lvcW6pIH;mJJJi\GmjdHnvck1qdmS3Y3XkJGRPSSCkcnXhb5M> NYjZ[|hNOTh7NUS3NVI>
HeLa MXnGeY5kfGmxbjDBd5NigQ>? MkDjNUDPxE1i NWH0bmRkOjRiaB?= MWfFcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDTMZBp[XOnIHHydoV{fA>? NILGZoUyQDl3NEexNi=>
T98G M3OycGZ2dmO2aX;uJGF{e2G7 M4n1c|Eh|ryPIB?= NHjvPGozPCCq MnTaSY5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgV{1xcGG|ZTDhdpJme3R? MoXmNVg6PTR5MUK=
L3 NH;5NnVEgXSxdH;4bYMhSXO|YYm= NVfLPJZJPSEQvF2g MlnTPVYhcA>? NXvLVI9oTE2VTx?= M1ryc3Nq\26rZnnjZY51dHliaX7obYJqfHNiY3XscEB{fXK4aY\hcC=> M1vsd|IxOTJ2NEW5
Granta-519 NH;6bW9EgXSxdH;4bYMhSXO|YYm= MWS1JO69VSB? M1P0NFk3KGh? NXPqXWVQTE2VTx?= NHe3NVNUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu MX:yNFEzPDR3OR?=
BT MUPDfZRwfG:6aXOgRZN{[Xl? MWW1JO69VSB? NVruSpBQQTZiaB?= MYPEUXNQ MnLJV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC|dYL2bZZidA>? NW[y[WZnOjBzMkS0OVk>
UPN2 NVK1WpBiS3m2b4TvfIlkKEG|c3H5 M160Z|Uh|ryPIB?= M{Xa[lk3KGh? NED1V|lFVVOR NUPhN4tEW2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?= MoLXNlAyOjR2NUm=
HBL-2 MWHDfZRwfG:6aXOgRZN{[Xl? MljwOUDPxE1i M1\hV|k3KGh? M{CyTmROW09? MVzTcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt MkjoNlAyOjR2NUm=
JVM-2 NWqxZ5g2S3m2b4TvfIlkKEG|c3H5 NXm2c|k3PSEQvF2g M4nRO|k3KGh? NHnYdVJFVVOR NUjwW5dtW2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?= NEPS[mEzODF{NES1PS=>
Z138 MlLzR5l1d3SxeHnjJGF{e2G7 MVu1JO69VSB? NWO4TXVHQTZiaB?= MkOxSG1UVw>? NX\4U5dWW2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?= MYqyNFEzPDR3OR?=
RWPE NFnmOnNKdn[jc3n2[UBCe3OjeR?= M2f2N|I2KM7:TR?= M3:xO|Q5KGh? MYLEUXNQ MoXqV4lodmmoaXPhcpRtgSC{ZXT1Z4V{KEWURz3kdol3\W5iY3XscEBqdn[jc3nvci=> MWqyNVU4PTh4NR?=
VCaP MmXlTY53[XOrdnWgRZN{[Xl? NXHh[mNuOjVizszN NULx[WhLPDhiaB?= NGW2dIdFVVOR NEfRcXhUcWewaX\pZ4FvfGy7IILl[JVk\XNiRWLHMYRzcX[nbjDj[YxtKGmwdnHzbY9v NHjTZnAzOTV5NUi2OS=>
Mouse H2AX−/− ES Cells NF2weWVEgXSxdH;4bYMhSXO|YYm= NGLVZlczNjVizszN NWD5cYZZOjBiaB?= Mk\DV4lodmmoaXPhcpRtgSCrbnjpZol1eyClZXzsJJN2en[rdnHs NGHO[m4zOzN3NUS4PS=>
Mouse ATM−/− ES Cells MXnDfZRwfG:6aXOgRZN{[Xl? M2DX[|IvPSEQvF2= M{KzSFIxKGh? MUfTbYdvcW[rY3HueIx6KGmwaHnibZR{KGOnbHygd5Vzfmm4YXy= MoHyNlM{PTV2OEm=
H1650 M3iwe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYKyNEDPxE1? MkTuNVQ1KGh? Mk[zTWM2OD1zNT60O{DPxE1? NV[zXnNzOjN{M{m4NFk>
H1650PTEN+ MoLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml2yNlAh|ryP NIq0UVEyPDRiaB?= NEH0T29KSzVyPUWwMlg{KM7:TR?= NF7hV|czOzJ|OUiwPS=>
PC-9 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEmyNWszOCEQvF2= M4n5fFE1PCCq M4fjT2lEPTB;NT64PEDPxE1? NE\yUG0zOzJ|OUiwPS=>
PC-9PTEN− NWjpV3RyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2S4R|IxKM7:TR?= NF;peZMyPDRiaB?= NIWzU2lKSzVyPU[uOVIh|ryP MVmyN|I{QThyOR?=
MDA-MB-231 MnfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITPUIY2KGSjeR?= NFHzS3RKSzVyPU[uPUDPxE1? NH\wTZkzOzd4MES5Oi=>
MDA-MB-468 NWX0VJlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDROUBl[Xl? NUS1b5Z5UUN3ME21MlAh|ryP NGXzWY4zOzd4MES5Oi=>
BT20 M3j1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LjTlUh\GG7 MmH3TWM2OD15Lkeg{txO NYDBU4JQOjN5NkC0PVY>
HCC1143 NH7ZWIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnmOUBl[Xl? NI\6OVRKSzVyPUGxMlEh|ryP NGKyZmozOzd4MES5Oi=>
HCC1937 NWXEcmZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\LOUBl[Xl? NVjZb3QxUUN3ME2xNk43KM7:TR?= M17nU|I{PzZyNEm2
Hs578t MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjVNpM2KGSjeR?= M2[wcWlEPTB;NT62JO69VQ>? M362UlI{PzZyNEm2
Hs578t(si) MnTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorCOUBl[Xl? NV;tbJV5UUN3ME23MlUh|ryP NVzvXFJPOjN5NkC0PVY>
BT474 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXiwS|gzPSCmYYm= NV3XZo5FUUN3ME2xPU45KM7:TR?= M13VVFI{PzZyNEm2
JIMT1 NET5OHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPH[YRFPSCmYYm= NXnwcpBFUUN3ME23Mlch|ryP MYSyN|c3ODR7Nh?=
SKBR3 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LLT|Uh\GG7 MX\JR|UxRTFzLkGg{txO MWOyN|c3ODR7Nh?=
SUM159 M2rMUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnlO3ZtPSCmYYm= NVrZTm1ZUUN3ME20MlIh|ryP Mnr6NlM4PjB2OU[=
CAMA1 MoTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjpVVJyPSCmYYm= MnLOTWM2OD1zNT64JO69VQ>? NU\yTJZrOjN5NkC0PVY>
MCF7 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX:1JIRigQ>? MnHBTWM2OD13Lkig{txO NWjTU2lROjN5NkC0PVY>
T47D NWXNemZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX[1JIRigQ>? MXLJR|UxRTlwNjFOwG0> M4i1bVI{PzZyNEm2
HCT116 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEn4dVcyODBizszN M3q3WlQ5KGh? MlLOSG1UVw>? MoHOTWM2OD1{LkWg{txOKA>? M1vwflI1PTd5OUSx
SW1116 M1TKb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\DNVAxKM7:TR?= MVG0PEBp M3;BemROW09? NELPVmFKSzVyPUGwNEDPxE1? M{LqU|I1PTd5OUSx
HT29 M{\vO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWr6cW51OTByIN88US=> NVzPTnNxPDhiaB?= Mn[xSG1UVw>? MnjKTWM2OD1zND63JO69VQ>? MUmyOFU4Pzl2MR?=
LoVo MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfxWXM3OTByIN88US=> NFzBPYs1QCCq M1\GVmROW09? MVXJR|UxRTF|LkSg{txO MlLKNlQ2Pzd7NEG=
HCT-15 MnnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DwblExOCEQvF2= M2mzeFQ5KGh? M4Pyd2ROW09? M2\nZWlEPTB;MUCg{txO MYeyOFU4Pzl2MR?=
SW48 M1uwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HPblExOCEQvF2= NXPWNm1UPDhiaB?= M2LJe2ROW09? M2nJR2lEPTB;OT61JO69VQ>? MYWyOFU4Pzl2MR?=
C-1 NHeyOmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rhTFExOCEQvF2= NWXPPYp1PDhiaB?= NYTLTII3TE2VTx?= NELpc3dKSzVyPUeuOkDPxE1? MnfsNlQ2Pzd7NEG=
RKO Ml\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1T0N|ExOCEQvF2= M4jvXFQ5KGh? M2C0XmROW09? MULJR|UxRTVwOTFOwG0> NXfuRpN{OjR3N{e5OFE>
HCT116 MlHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPzNVAxKM7:TR?= M{i3clQ5KGh? Mk\MSG1UVw>? MnziVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>? MmK4NlQ2Pzd7NEG=
SW1116 NGSzdFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITJO5QyODBizszN NXTBOnlrPDhiaB?= NXrUOoVDTE2VTx?= Mn;XVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>? MkHMNlQ2Pzd7NEG=
HT29 MnzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3O5UFExOCEQvF2= NX3STodSPDhiaB?= M2rHRWROW09? M1TySXBwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB? MmTmNlQ2Pzd7NEG=
LoVo NGTJNmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrTNZgyODBizszN MVO0PEBp Mkj6SG1UVw>? MX7Qc5RmdnSrYYTld{BUVi1|ODDjfZRwfG:6aXPpeJkh NHT6ZnYzPDV5N{m0NS=>
SW48 M4Dn[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PGPVExOCEQvF2= MnjiOFghcA>? NUjpbow1TE2VTx?= NVXiUI9HWG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= MXyyOFU4Pzl2MR?=
C-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUixNFAh|ryP M17qd|Q5KGh? NV\6c2o6TE2VTx?= NV;VfmQ3WG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= M2ezWFI1PTd5OUSx
RKO MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HOVFExOCEQvF2= MofxOFghcA>? MXLEUXNQ MnfzVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>? M3rDN|I1PTd5OUSx
HCT116 NFTVfVJHfW6ldHnvckBCe3OjeR?= NFHmXnkyOCCwTR?= NFS1TmQyOiCq NVK3W2MzTE2VTx?= NFHjendKdmO{ZXHz[ZMhTE6DIHTveYJt\S2|dILhcoQh[nKnYXvzJIlv\HWlZXSgZpkhW05vM{i= M1nZbFI1PTd5OUSx
HT29 NUfscGFpTnWwY4Tpc44hSXO|YYm= MmHDNVAhdk1? NWjjU4VuOTJiaB?= MmP3SG1UVw>? MmXETY5kemWjc3XzJGRPSSCmb4XicIUue3S{YX7kJIJz\WGtczDpcoR2[2WmIHL5JHNPNTN6 NFWxfIwzPDV5N{m0NS=>
TE-6 NGHCXpBHfW6ldHnvckBCe3OjeR?= MXy1JO69VSB? MlniNVIhcA>? Mn;4SG1UVw>? NEfjZpJKdmS3Y3XzJGczN01iYYLy[ZN1 M1TtfFI1OjF7MU[0
TE-6 MYHGeY5kfGmxbjDBd5NigQ>? M2fWbFUh|ryPIB?= NGPtXZgzPCCq Ml[3SG1UVw>? NVHZcJE3UW6lcnXhd4V{KGmwIHTveYJt\SC|dILhcoQh[nKnYXvzJEhFW0K|KR?= NFfGb3AzPDJzOUG2OC=>
Hep3B MkjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXS0NEDPxE1i NVm4WIZ4PzJiaB?= Mn\SSG1UVw>? M1Lpc3N6dmW{Z3nzeIlk[WyueTDpcohq[mm2czDj[YxtKGe{b4f0bEB4cXSqIFTIUWVS NHnOTWwzPTB5Mke1Ni=>
Huh7 MlHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXWXng1OCEQvF2g M2ryO|czKGh? M{npSGROW09? M3\wb3N6dmW{Z3nzeIlk[WyueTDpcohq[mm2czDj[YxtKGe{b4f0bEB4cXSqIFTIUWVS NVTjU|FFOjVyN{K3OVI>
Hep3B NXz1UZhITnWwY4Tpc44hSXO|YYm= NH7OXpY1OCEQvF2g NWryU4EyOjRiaB?= NHi1VXdFVVOR Ml[yTY5lfWOnczDSU3MheHKxZIXjeIlwdiC5aYToJGRJVUWT NYe2XGRsOjVyN{K3OVI>
Huh7 NYPYTWd{TnWwY4Tpc44hSXO|YYm= Mlq5OFAh|ryPIB?= MlrZNlQhcA>? MXfEUXNQ M3q5Xmlv\HWlZYOgVm9UKHC{b3T1Z5Rqd25id3n0bEBFUE2HUR?= M3TIWlI2ODd{N{Wy
Hep3B NVy2emVzTnWwY4Tpc44hSXO|YYm= NVzLfFY6PDBizszNJC=> NILCXnYzPCCq M1m0RmROW09? MlHKTY5lfWOnczDj[YxtKGG3dH;wbIFogSC5aYToJGRJVUWT NGjjTWEzPTB5Mke1Ni=>
Huh7 NXnmPJBUTnWwY4Tpc44hSXO|YYm= NGe4ZpY1OCEQvF2g NXnoRpVlOjRiaB?= NYjMR|RNTE2VTx?= MnG5TY5lfWOnczDj[YxtKGG3dH;wbIFogSC5aYToJGRJVUWT MX6yOVA4Ojd3Mh?=
SGC-7901 NILnUHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnGN|DDqM7:TR?= NETGPVI1QCCq MoLOSG1UVw>? NYfaWmp4SmyxY3ugc5hidGmybHH0bY4ucW6mdXPl[EBk\WyuIHTlZZRp MYiyOVc3PzB5Nh?=
COLO-800 NWT6[W9jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfWXW9NUUN3ME2wMlQ1OTZ2IN88US=> NEjxRYtUSU6JRWK=
EoL-1- NHnxdGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\BTWM2OD1yLkW2OFQ3KM7:TR?= M2XLVXNCVkeHUh?=
NCI-H209 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTycplKSzVyPUCuPVE2PTZizszN M4jzVnNCVkeHUh?=
ES1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTFwMUG0NFgh|ryP NWnhXlY6W0GQR1XS
NKM-1 NWC3WnZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTFwMkWzOFch|ryP M4j5NnNCVkeHUh?=
NTERA-S-cl-D1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3QfYNKSzVyPUGuN|M{PDFizszN MWDTRW5ITVJ?
MHH-ES-1 MoTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHMTWM2OD1zLk[yNFY4KM7:TR?= NHLGN5BUSU6JRWK=
ES8 NFe2TFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHm1c41KSzVyPUGuO|I1OTRizszN NXe2bXZlW0GQR1XS
NCI-H720 NHHGZ4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2C4[GlEPTB;Mj6yNFY6QSEQvF2= NEjlWlRUSU6JRWK=
EW-3 NXrU[2wzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTJwMke1N|Qh|ryP NF\tNmJUSU6JRWK=
D-566MG NVTsNYlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXQVFRKSzVyPUKuOFQ2PjhizszN Mk\MV2FPT0WU
697 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fETWlEPTB;Mj64OFE4OyEQvF2= MkjUV2FPT0WU
ES5 NE\C[ZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITjV4VKSzVyPUKuPFgyQDlizszN M1m5enNCVkeHUh?=
COLO-684 NXX0[2NuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPITWM2OD1|LkWxOlk3KM7:TR?= MWrTRW5ITVJ?
ML-2 MlK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rvbGlEPTB;Mz62NFA2QCEQvF2= MXTTRW5ITVJ?
MC-IXC MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvXTWM2OD1|Lk[zN|k{KM7:TR?= MkTHV2FPT0WU
DB NHSwdmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHTdJVKSzVyPUOuOlU1PDhizszN Mn74V2FPT0WU
HCC2218 MmLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHVWZpkUUN3ME2zMlc{OTB|IN88US=> MULTRW5ITVJ?
NCI-H510A Mn\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jlcGlEPTB;Mz64NlczPCEQvF2= MVPTRW5ITVJ?
NCI-H526 NUG3WY5OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjucHRKSzVyPUOuPFY6PThizszN NV3kRZB5W0GQR1XS
MV-4-11 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zZZ2lEPTB;ND6xN|M{PCEQvF2= NFzhNoJUSU6JRWK=
PA-1 Ml24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTRwMkWyPUDPxE1? MWHTRW5ITVJ?
EW-22 M{PRcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFS4eFVKSzVyPUSuN|U5PiEQvF2= MWDTRW5ITVJ?
KASUMI-1 NVXvU3FQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PiSGlEPTB;ND60NFExQSEQvF2= MU\TRW5ITVJ?
LU-139 NUW5OVRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\MTWM2OD12Lke1PFI6KM7:TR?= M33XfnNCVkeHUh?=
SBC-1 NULuVFFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLNWJVpUUN3ME20MlgxQTB6IN88US=> MXzTRW5ITVJ?
H4 MkfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\uWmlEPTB;ND64PVQ1OyEQvF2= Ml3nV2FPT0WU
EW-11 MmrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWO5bnF[UUN3ME21MlA5ODd{IN88US=> Ml;xV2FPT0WU
NBsusSR NUS0eY1LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILjSpBKSzVyPUWuNVIxPTVizszN M4f1ZnNCVkeHUh?=
RPMI-8226 NITzdXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPNdm93UUN3ME21MlE2OjR2IN88US=> MkL6V2FPT0WU
DEL NES1cphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTVwMkCwNFYh|ryP MYDTRW5ITVJ?
ES4 NXz3bYI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULlOWdIUUN3ME21MlUyOzh7IN88US=> M4rqZnNCVkeHUh?=
GCT MlLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rUUGlEPTB;NT61Olg2PiEQvF2= M2jJN3NCVkeHUh?=
NCI-H1048 M1fnWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTVwOUeyO|Mh|ryP M2XufHNCVkeHUh?=
NCI-SNU-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXXTWM2OD14LkCyNkDPxE1? MXjTRW5ITVJ?
ES7 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTZwMEO1O|ch|ryP Mn\rV2FPT0WU
SW982 NEH5VphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTZwMEmxN|ch|ryP NEXKVIdUSU6JRWK=
L-363 NIDv[ZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLCdGtwUUN3ME22MlM{QTd2IN88US=> MVTTRW5ITVJ?
HT-1080 Mlj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\qV3BKSzVyPU[uOFk3QDNizszN MYfTRW5ITVJ?
HAL-01 M1nYRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTZwNUGwPUDPxE1? NVf1bnplW0GQR1XS
NB14 M3zIemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPSTXV3UUN3ME22MlY1ODN7IN88US=> NUjPUYVsW0GQR1XS
EW-13 MnnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWqw[ZI1UUN3ME22Mlc4PDJ2IN88US=> MkTzV2FPT0WU
NY MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;wSZJKSzVyPU[uPVQ3ODVizszN M{nBTHNCVkeHUh?=
NCI-SNU-5 NV7O[4FOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTdwMUC0N|Mh|ryP Mo\hV2FPT0WU
MS-1 M{[zO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTdwMUe0PVQh|ryP MX\TRW5ITVJ?
EW-16 NGHaO5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTdwM{G4OlEh|ryP M{jTbXNCVkeHUh?=
LU-65 NHvMdYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTdwNEi0NVch|ryP NE\2bndUSU6JRWK=
HGC-27 MnjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTdwN{KxO|Mh|ryP MYPTRW5ITVJ?
CTB-1 NXriToVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zhRmlEPTB;Nz63OlE4PSEQvF2= MYjTRW5ITVJ?
5637 NUDPXGhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PyZWlEPTB;Nz65Nlg3KM7:TR?= NUXwWGhiW0GQR1XS
U251 NV;aNJdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWe0PJo4UUN3ME23Mlk1ODF4IN88US=> NUXjXVNbW0GQR1XS
HOS NGK5U|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRThwMkOwNFch|ryP Mk\5V2FPT0WU
DOHH-2 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{e0bWlEPTB;OD6yN|U5KM7:TR?= NFiyNphUSU6JRWK=
EW-1 MlrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DSTmlEPTB;OD6zNFA5QCEQvF2= NV\mT4lqW0GQR1XS
BV-173 NILlSo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRThwNUW1OEDPxE1? NIjsR3hUSU6JRWK=
8-MG-BA NHq2T45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXuTWM2OD16Lk[4PVg5KM7:TR?= MlTIV2FPT0WU
NB69 NFXEflVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRThwN{C5NlEh|ryP NILBWW9USU6JRWK=
NCI-H69 NEfGVVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITHPJJKSzVyPUmuPVA6PjFizszN MVnTRW5ITVJ?
RS4-11 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjnTWM2OD1zMT6yNlA5KM7:TR?= M{XUcnNCVkeHUh?=
ONS-76 MmHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLGTWM2OD1zMT6yPVQ4KM7:TR?= MnrYV2FPT0WU
SF539 NH\0UHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPXVXVtUUN3ME2xNU41QDh7IN88US=> MV3TRW5ITVJ?
HuO-3N1 NHnIUW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXSTWM2OD1zMT61O|k3KM7:TR?= M1SzNnNCVkeHUh?=
NCI-H1651 NF3JRWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;RcYl7UUN3ME2xNk4{OTF3IN88US=> M4DhbHNCVkeHUh?=
KARPAS-45 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmOzTWM2OD1zMj6zO|Yh|ryP MmG3V2FPT0WU
SK-NEP-1 M4T1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTF{LkS2NFkh|ryP MoHTV2FPT0WU
LAMA-84 M1HT[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3qVopWUUN3ME2xN{4yODl3IN88US=> NGnxcnZUSU6JRWK=
NCI-H1155 M2DjPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjHb5puUUN3ME2xN{4zQDV4IN88US=> MnjUV2FPT0WU
CTV-1 MmXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zVU2lEPTB;MUOuOFQ2KM7:TR?= NUfZTolLW0GQR1XS
QIMR-WIL NInnemlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTF|Lke4NVQh|ryP NVT3[|J4W0GQR1XS
H9 NIrteGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHwco1KSzVyPUGzMlg1PzVizszN MWjTRW5ITVJ?
SK-MEL-1 NELWfpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzITWM2OD1zMz65N|Q4KM7:TR?= NUTGNnlQW0GQR1XS
HD-MY-Z NUTHd2xYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\vd2lEPTB;MUSuNFY{PyEQvF2= MWXTRW5ITVJ?
TI-73 MknBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjaTWM2OD1zND6yN|U3KM7:TR?= NXrvNGpDW0GQR1XS
JVM-3 M37XbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTDTWM2OD1zNT61O|E3KM7:TR?= NGLnSFFUSU6JRWK=
D-247MG MlTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUe3RZdPUUN3ME2xOU42QTNizszN NV;Ve2hDW0GQR1XS
VA-ES-BJ NYLocm41T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkSyTWM2OD1zNT62NFk4KM7:TR?= MoDoV2FPT0WU
NOS-1 NIrKR|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLzTWM2OD1zNT62OVIzKM7:TR?= NHTzSoRUSU6JRWK=
MOLT-4 NGO4OnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnPZYtvUUN3ME2xOk44PTJizszN NGPycopUSU6JRWK=
Mo-T MoHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXsPJJKSzVyPUG3MlA5PDlizszN MV3TRW5ITVJ?
NCI-H1770 Ml3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXUTWM2OD1zNz6xOVQ{KM7:TR?= MYXTRW5ITVJ?
COLO-320-HSR NV;ERlBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zTZWlEPTB;MUeuNVgzPyEQvF2= M3LKbHNCVkeHUh?=
TE-12 NHjw[HpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTF5LkewOVQh|ryP MlPZV2FPT0WU
NCI-H82 MnzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjafnVKSzVyPUG3Mlg4OjhizszN M4DXOXNCVkeHUh?=
NEC8 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTF6LkGzNVYh|ryP MYTTRW5ITVJ?
HSC-3 M130WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTF6Lke0NVQh|ryP NFGzdoJUSU6JRWK=
NCI-H1092 MlvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPIV3gxUUN3ME2xPE44PTl3IN88US=> NWOwToRMW0GQR1XS
NCI-H292 MoO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XibWlEPTB;MUmuNFQ5QSEQvF2= MlTmV2FPT0WU
L-428 M4D0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXuVHZKSzVyPUG5MlU2QSEQvF2= MUXTRW5ITVJ?
LU-134-A NYPLUW1zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPUTWM2OD1zOT61O|Ih|ryP MljLV2FPT0WU
GI-ME-N Ml7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfJbVRFUUN3ME2xPU42PzR5IN88US=> MojHV2FPT0WU
ALL-PO NYH3OFh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDQZYh{UUN3ME2xPU42QTd{IN88US=> MVfTRW5ITVJ?
D-283MED NIPoNJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTF7LkmxOUDPxE1? NFvzUHBUSU6JRWK=
D-423MG MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnyTWM2OD1zOT65PVY4KM7:TR?= MVfTRW5ITVJ?
CAKI-1 NXfkNIFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPjNWdlUUN3ME2yNE4zOjF7IN88US=> MVjTRW5ITVJ?
ETK-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnnXJRTUUN3ME2yNE4zPjF3IN88US=> MmO5V2FPT0WU
G-402 M{fKO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTJyLkWzN|Qh|ryP NXXXN2tUW0GQR1XS
HL-60 M13QfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofrTWM2OD1{MT6xOlE{KM7:TR?= M1n0TXNCVkeHUh?=
A2058 NIfuTVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTSVpJKSzVyPUKxMlQ1PzdizszN NEn2flJUSU6JRWK=
CHP-212 NF;4NYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTJzLkmwOVEh|ryP NHryO5RUSU6JRWK=
KY821 NH6wbmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\nTWM2OD1{MT65O|Uh|ryP M{\lfHNCVkeHUh?=
TYK-nu NFfVT41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrwbYZsUUN3ME2yNk4xPjVzIN88US=> M1vJZnNCVkeHUh?=
JVM-2 NEmybnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTqVYhKSzVyPUKyMlI6QDNizszN MnvTV2FPT0WU
KU812 NGLYeXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV:yWJFTUUN3ME2yNk44OzF{IN88US=> Mkj3V2FPT0WU
MKN28 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTJ{LkmwNVUh|ryP MXTTRW5ITVJ?
ECC10 M3zKSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPXcIRKUUN3ME2yN{44PDFizszN M3\WZnNCVkeHUh?=
BHT-101 MmLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjHTWM2OD1{ND6wNFA5KM7:TR?= NV[0NpVGW0GQR1XS
DU-4475 M2jsNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLkTWM2OD1{ND6zN|M4KM7:TR?= NX7xW5I5W0GQR1XS
769-P MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTJ2Lki0OlYh|ryP MluyV2FPT0WU
HEC-1 NHHycYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmniTWM2OD1{NT60OFUh|ryP M1LtXXNCVkeHUh?=
MOLT-13 M4[2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlL1TWM2OD1{NT61N|MyKM7:TR?= NFv4ZoRUSU6JRWK=
8505C NFixXFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIO5ZZJKSzVyPUK2MlQ6PzdizszN Mnz0V2FPT0WU
GB-1 M2TwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLiTWM2OD1{Nj63NVc3KM7:TR?= MlvSV2FPT0WU
SF126 NWrDSJNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTJ4Lke2OFgh|ryP MnzTV2FPT0WU
A4-Fuk M1zoR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTJ5LkGyO|Eh|ryP NWPreJBkW0GQR1XS
OVCAR-8 Mnr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTJ5LkG1N|kh|ryP NUSwU4h2W0GQR1XS
NCI-H1304 M4HMO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUn4ZoxrUUN3ME2yO{42PCEQvF2= MVXTRW5ITVJ?
GR-ST MlO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jJcmlEPTB;MkiuNFQ4KM7:TR?= MVvTRW5ITVJ?
G-401 M3:wTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{e4O2lEPTB;MkiuOVA6PiEQvF2= M2DhW3NCVkeHUh?=
LXF-289 M3LteWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnnVVduUUN3ME2yPE42PjVzIN88US=> NV3Wb4JMW0GQR1XS
DBTRG-05MG NXLlNXNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTJ6LkmyNFQh|ryP M4fYVHNCVkeHUh?=
YKG-1 NE\DfmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nSeWlEPTB;MkmuPFY5KM7:TR?= NWm0VJYyW0GQR1XS
GAMG MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlm3TWM2OD1{OT65PVMh|ryP M2rOUXNCVkeHUh?=
HCT-116 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HSXmlEPTB;M{CuNFU1QCEQvF2= MVrTRW5ITVJ?
S-117 MkTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTNzLkKyOVch|ryP MnrxV2FPT0WU
NCI-H1693 M37weGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTN|Lk[1OFIh|ryP NWDXR2x7W0GQR1XS
A427 M4\EOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfoRWJ6UUN3ME2zN{46QTd4IN88US=> NUW3WYJPW0GQR1XS
HT-29 M2rDVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\ZPWZKSzVyPUO0MlYxOzJizszN NIDHSZZUSU6JRWK=
P12-ICHIKAWA M17vT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTN2Lke0PVEh|ryP NYLzclg{W0GQR1XS
CAL-51 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[0TWM2OD1|NT6wO|A6KM7:TR?= MUDTRW5ITVJ?
Ramos-2G6-4C10 NWLuOmRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjJdIN[UUN3ME2zOU4zPDJ3IN88US=> NYD3WpRHW0GQR1XS
SCH MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTN4LkSxO|Qh|ryP MVHTRW5ITVJ?
SK-MEL-24 M3nvVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fRXmlEPTB;M{[uPVA1PCEQvF2= MofEV2FPT0WU
SW1573 NX;sXZVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\EbHpKSzVyPUO4MlczOTZizszN MXLTRW5ITVJ?
BALL-1 MlX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\4TWM2OD1|OT6yNVI6KM7:TR?= M3X5XXNCVkeHUh?=
BE-13 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\1PWlEPTB;M{muN|I6KM7:TR?= M2Th[nNCVkeHUh?=
GI-1 M4XWVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fIO2lEPTB;M{muPFY1PyEQvF2= Mn;1V2FPT0WU
GOTO NXKwd4ZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjpS2lKSzVyPUO5MlkyOzlizszN Ml3xV2FPT0WU
A673 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfEdFJ5UUN3ME20NU4xOzR|IN88US=> MmrvV2FPT0WU
KG-1 NGXqbHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTR|LkO5OEDPxE1? MnK5V2FPT0WU
GP5d NW\qcY1NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXKXoFKSzVyPUS0MlA3PjZizszN MV\TRW5ITVJ?
MFM-223 MoXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;ZPIp[UUN3ME20OE4yOjJ6IN88US=> M2XzOXNCVkeHUh?=
OAW-42 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTR2LkK2OFMh|ryP NEKySoZUSU6JRWK=
C8166 NHPlWohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPmcXd1UUN3ME20OU4xQDJ{IN88US=> MlK5V2FPT0WU
LU-99A NETRdIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGq0eoFKSzVyPUS2MlE{OjJizszN M172S3NCVkeHUh?=
NCI-H23 MoPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDMTWM2OD12Nj6xO|g2KM7:TR?= MUHTRW5ITVJ?
HO-1-N-1 NHLKcoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfKSZZjUUN3ME20O{4xQTl6IN88US=> MkLlV2FPT0WU
A3-KAW NILQfFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYD6OXFZUUN3ME20O{4yODB5IN88US=> M1;QR3NCVkeHUh?=
CGTH-W-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTR5LkWwOlkh|ryP M3zEVHNCVkeHUh?=
DJM-1 NUjndZNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLjTWM2OD12Nz61OFE{KM7:TR?= MWHTRW5ITVJ?
A101D NIO5ZllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{O0NGlEPTB;NEeuOlM2PyEQvF2= NW\kUJVXW0GQR1XS
BB30-HNC MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LrZ2lEPTB;NEiuN|A4OiEQvF2= NIX6UGdUSU6JRWK=
T98G NHvPWIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3OxfmlEPTB;NEiuOFY{OyEQvF2= NXLJR2xGW0GQR1XS
NCI-H1573 M{LwdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;TdmlEPTB;NEmuOFQ3OiEQvF2= NH\ZfHBUSU6JRWK=
MEG-01 M3vPdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIq3XJlKSzVyPUS5Mlc1OTFizszN NYSzdoRJW0GQR1XS
WM-115 NWnYRVZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInpUGpKSzVyPUS5MlkzOjJizszN NILRPGVUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western Blot
DR5/CHOP; 

PubMed: 25531448     


(A) U87 GBM cells were treated with Olaparib (10 µM) for the indicated time points, subjected to immunoblotting and analyzed for the expression of DR5. B-D) U87 (B), U373 (C) and LN229 GBM cells (D) were treated with increasing concentrations of Olaparib (µM) for 7 hours, subjected to immunoblotting and analyzed for the expression of CHOP and DR5. E–F) MDA-MB-468 (E) and MDA-MB-436 (F) were treated with increasing concentrations (µM) of Olaparib for 7 hours, harvested for immunoblotting and analyzed for the expression of DR5.

γH2AX/H2AX; 

PubMed: 22933245     


FK866 exacerbates levels of γH2AX caused by olaparib. CAL51 cells were exposed to FK866 and/or olaparib for 48 h and cell lysates generated and immunoblotted for total and γH2AX.

pATM; 

PubMed: 27686740     


(C) Western blot analysis in HN9-cisR cells according to changes in olaparib doses. Olaparib induced pATM and 53BP1 activation in a dose-dependent manner in HN9-cisR cells. 

53BP1; 

PubMed: 27686740     


(C) Western blot analysis in HN9-cisR cells according to changes in olaparib doses. Olaparib induced pATM and 53BP1 activation in a dose-dependent manner in HN9-cisR cells. 

NF-kB; 

PubMed: 27686740     


(C) Western blot analysis in HN9-cisR cells according to changes in olaparib doses. Olaparib induced pATM and 53BP1 activation in a dose-dependent manner in HN9-cisR cells. 

pS6/S6; 

PubMed: 24831086     


HCC1937 cells (BRCA1-inactive) were treated with 10 nM olaparib with indicated times. Whole-cell lysates were prepared and analyzed by Western blotting with the indicated antibodies. 

25531448 22933245 27686740 24831086
Immunofluorescence
DNA damage; 

PubMed: 27686740     


(A) A comet assay and (B) γH2AX immunofluorescence assay were performed 72 h after olaparib treatment to identify DNA damage. A relatively higher level of DNA damage was observed in HN9-cisR cells; however, olaparib also induced slight DNA damage in olaparib-resistant HN4-cisR cells. Magnification: × 100 (comet assay); × 400 (γH2AX).

γH2AX; 

PubMed: 28069876     


Representative images of immunofluorescence (IF) staining for γH2AX in 22RV1 cells treated with of BI2536 (5 nM), Olaparib (10 µM) or both for 24 h. 22RV1 cells (1 × 105) were plated in 6-well plates on day 0 and then treated with BI2536, Olaparib or both for 24 h.

27686740 28069876
Growth inhibition assay
Cell viability ; 

PubMed: 25531448     


A-D): U87 (A), U373 (B), LN229 (C) and MDA-MB-468 (D) cells were treated with suboptimal dosages of TRAIL (A: 100 ng/ml, B: 25 ng/ml, C: TRAIL 200 ng/ml, D: 10 ng/ml), Olaparib (A–C: 10 µM, D: 5 µM) or the combination of both reagents for 48 hours. Thereafter, MTT assays were performed to determine cellular viability.

25531448
ELISA
IL-8; 

PubMed: 28456021     


ELISA measuring PAR levels in Akata-EBV cells. Cells were treated with 2.5 μM olaparib for 24 h to inhibit PARP activity. Data are shown as pg of PAR per μg of protein. 

GLP-1; 

PubMed: 29392078     


Olaparib enhances promotes GLP-1 secretion in NCI-H716 cells Cells were stimulated for 30 minutes with or without 16 mM glucose. GLP-1 was measured by ELISA. Bars represent the mean of three independent experiments normalized to the control. Error bars indicate standard deviation. Statistical analyses were performed by two-tailed Student’s t-test and significance is denoted by asterisks where *P<0.05.

28456021 29392078
In vivo Combining with temozolomide, Olaparib (10 mg/kg, p.o.) significantly suppresses tumor growth in SW620 xenografts. [1] Olaparib shows great response to Brca1-/-;p53-/- mammary tumors (50 mg/kg i.p. per day), while no responses to HR-deficient Ecad-/-;p53-/- mammary tumors. Olaparib even does not show dose-limiting toxicity in tumor-bearing mice. [3] Olaparib has been used to treat with BRCA mutated tumors, such as ovarian, breast and prostate cancers. Moreover, Olaparib shows selectively inhibition to ATM (Ataxia Telangiectasia Mutated)-deficient tumor cells, which indicates to be a potential agent for treating ATM mutant lymphoid tumors. [4]

Protocol

Kinase Assay:

[1]

- Collapse

FlashPlate assay (96-well screening assay):

To columns 1 through 10, 1 μL of Olaparib (in DMSO) is added, and 1 μL DMSO only is added to the positive (POS) and negative (NEG) control wells (columns 11 and 12, respectively) of a pretreated FlashPlate. PARP-1 is diluted 1:40 in buffer (buffer B: 10% glycerol (v/v), 25 mM HEPES, 12.5 mM MgCl2,50 mM KCl, 1 mM DTT, 0.01% NP-40 (v/v), pH 7.6) and 40 μL added to all 96 wells (final PARP-1 concentration in the assay is ~1 ng/μL). The plate is sealed and shaken at RT for 15 min. Following this, 10 μL of positive reaction mix (0.2 ng/μL of double-stranded oligonucleotide [M3/M4] DNA per well, 5 μM of NAD+ final assay concentration, and 0.075 μCi 3H-NAD+ per well) is added to the appropriate wells (columns 1-11). The negative reaction mix, lacking the DNA oligonucleotide, is added to column 12 (with the mean negative control value used as the background). The plate is resealed and shaken for a further 60 min at RT to allow the reaction to continue. Then, 50 μL of ice-cold acetic acid (30%) is added to each well to stop the reaction, and the plate is sealed and shaken for a further 60 min at RT. Tritiated signal bound to the FlashPlate is then determined in counts per minute (CPM) using the TopCount plate reader.
Cell Research:

[1]

- Collapse
  • Cell lines: Breast cancer cell lines including SW620 colon, A2780 ovarian, HCC1937, Hs578T, MDA-MB-231, MDA-MB-436, and T47D
  • Concentrations: 1-300 nM
  • Incubation Time: 7-14 days
  • Method:

    The cytotoxicity of Olaparib is measured by clonogenic assay. Olaparib is dissolved in DMSO and diluted by culture media before use. The cells are seeded in six well plates and left to attach overnight. Then Olaparib is added at various concentrations and the cells are incubated for 7-14 days. After that the surviving colonies are counted for calculating the IC50.


    (Only for Reference)
Animal Research:

[3]

- Collapse
  • Animal Models: Brca1-/-;p53-/- mammary tumors are generated in K14cre;Brca1F/F;p53F/F mice.
  • Dosages: 50 mg/kg
  • Administration: Administered via i.p. injection at 10 μL/g of body weight
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 86 mg/mL warmed (197.94 mM)
Water 0.002 mg/mL (0.0 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 434.46
Formula

C24H23FN4O3

CAS No. 763113-22-0
Storage powder
in solvent
Synonyms Ku-0059436
Smiles FC1=C(C=C(CC2=NNC(=O)C3=C2C=CC=C3)C=C1)C(=O)N4CCN(CC4)C(=O)C5CC5

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04298021 Not yet recruiting Drug: AZD6738|Drug: Durvalumab|Drug: Olaparib Bile Duct Cancer|Chemotherapy Effect Seoul National University Hospital April 1 2020 Phase 2
NCT04330040 Not yet recruiting Drug: Olaparib Ovarian Cancer|Breast Cancer AstraZeneca March 31 2020 Phase 4
NCT04005690 Recruiting Drug: Cobimetinib|Drug: Olaparib Borderline Resectable Pancreatic Adenocarcinoma|Locally Advanced Pancreatic Ductal Adenocarcinoma|Metastatic Pancreatic Ductal Adenocarcinoma|Resectable Pancreatic Ductal Adenocarcinoma|Stage I Pancreatic Cancer AJCC v8|Stage IA Pancreatic Cancer AJCC v8|Stage IB Pancreatic Cancer AJCC v8|Stage II Pancreatic Cancer AJCC v8|Stage IIA Pancreatic Cancer AJCC v8|Stage IIB Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8 OHSU Knight Cancer Institute|National Cancer Institute (NCI)|Oregon Health and Science University August 1 2019 Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to prepare the solution of the compound (S1060) for in vivo study?

  • Answer:

    We recommend the following formulation: 4% DMSO+30% PEG300+ 66%H2O. It is a clear solution and can be used for IP injection.

  • Question 2:

    I saw that the solubility of the compound for in vivo on the website had been changed, why the change has been made?

  • Answer:

    For the formulation for in vivo, the compound dissolving in 15% Captisol (former solubility) is a suspension, and it is fine for oral gavage. And now, dissolving in 4% DMSO+30% PEG 300+ddH2O is a clear solution, and is for injection.

  • Question 3:

    How long can the chemical compound be stable in DMEM at 4 °C?

  • Answer:

    The compound is stable in DMEM at 4 degree for one week.

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Tags: buy Olaparib (AZD2281) | Olaparib (AZD2281) supplier | purchase Olaparib (AZD2281) | Olaparib (AZD2281) cost | Olaparib (AZD2281) manufacturer | order Olaparib (AZD2281) | Olaparib (AZD2281) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID